Apply Give

Other ways to search: Events Calendar | UTHSC

 Mother hopes daughter will benefit from new FDA approved sickle cell treatment

Written by Communications and Marketing

|

Patients with sickle cell disease will soon have a new treatment option to reduce pain crises caused by obstructed blood flow. The FDA has approved use of the drug crizanlizumab based on the results of a clinical trial led by Kenneth Ataga, MD, Plough Foundation Endowed Chair in Sickle Cell Disease and director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center.

Top Publishers